CoChat
Sign Up
Cited by 231Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy

Open access
Huang, Xing, Zhang, Xiaozhen, Li, Enliang, Zhang, Gang, Wang, Xun, Tang, Tianyu, Bai, Xueli, Liang, Tingbo·2020·Journal of Hematology & Oncology
DOI 10.1186/s13045-020-00917-yPMC PMC7325042
Open this paper in CoChat — free accountOpen PDF

Abstract

VISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity than previously recognized. Here, we review the current knowledge on the therapeutic phenotypes and molecular mechanisms that underlie the contradictory roles of VISTA in checking anti-cancer immune responses. Furthermore, we highlight the potential indeterminacy of VISTA-targeted strategies in cancer immunotherapy, with in silico analyses. In fact, VISTA functions like a homeostatic regulator that actively normalizes immune responses. Thus, the regulatory role of VISTA in anti-cancer immunity remains to be fully elucidated.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-020-00917-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. [1]Couzin-Frankel J CanceriImmunotherapy Science 2013 342 6165 1432 1433 24357284
  2. [2]Mellman I Coukos G Dranoff G Cancer immunotherapy comes of age Nature 2011 480 7378 480 489 22193102 PMC3967235
  3. [4]Wang L VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses J Exp Med 2011 208 3 577 592 21383057 PMC3058578
  4. [6]ElTanbouly MA VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity Semin Immunol 2019 42 101308 31604531 PMC7233310
  5. [7]Flies DB Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models J Immunol 2011 187 4 1537 1541 21768399 PMC3150865
  6. [9]Yoon KW Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53 Science 2015 349 6247 1261669 26228159 PMC5215039
  7. [10]Bharaj P Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals PLoS One 2014 9 10 e109103 25279955 PMC4184823
  8. [11]Flies DB Higuchi T Chen L Mechanistic assessment of PD-1H coinhibitory receptor-induced T cell tolerance to allogeneic antigens J Immunol 2015 194 11 5294 5304 25917101 PMC4433880
  9. [12]Flies DB Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity J Clin Invest 2014 124 5 1966 1975 24743150 PMC4001557
  10. [13]Villarroel-Espindola F Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer Clin Cancer Res 2018 24 7 1562 1573 29203588 PMC5884702
  11. [14]Gao J VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer Nat Med 2017 23 5 551 555 28346412 PMC5466900
  12. [15]Xie S Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors Cancer Immunol Immunother 2018 67 11 1685 1694 30128738 PMC11028359
  13. [16]ElTanbouly MA. et al. Coming of age as a multi-lineage immune checkpoint. Clin Exp Immunol: VISTA; 2020. PMC7160665 31930484
  14. [17]Blando J Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer Proc Natl Acad Sci U S A 2019 116 5 1692 1697 30635425 PMC6358697
  15. [18]Xu W Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression Cancer Immunol Res 2019 7 9 1497 1510 31340983 PMC6726548
  16. [19]Rosenbaum, S.R., et al., FOXD3 regulates VISTA expression in melanoma. Cell Reports, 2020. 30(2): p. 510-524. e6. PMC6995351 31940493
  17. [20]Kondo Y Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma Oral Oncol 2016 57 54 60 27208845
  18. [21]Liu J Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses Proc Natl Acad Sci 2015 112 21 6682 6687 25964334 PMC4450438
  19. [22]Kakavand H Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients Mod Pathol 2017 30 12 1666 1676 28776578
  20. [23]Xie X High-density infiltration of V-domain immunoglobulin suppressor of T-cell activation up-regulated immune cells in human pancreatic cancer Pancreas 2018 47 6 725 731 29771768
  21. [24]Byers JT Expression of the novel costimulatory molecule B7-H5 in pancreatic cancer Ann Surg Oncol 2015 22 3 1574 1579 25519928
  22. [25]Ni L Dong C New checkpoints in cancer immunotherapy Immunol Rev 2017 276 1 52 65 28258699
  23. [26]Hong S Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy Protein Cell 2019 10 11 840 845 31236852 PMC6834738
  24. [27]Hernandez-Martinez J-M VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy J Thoracic Dis 2018 10 12 6378 6382 PMC6344701 30746169
  25. [28]Brcic L Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung Virchows Arch 2018 472 4 589 598 29520483 PMC5924661
  26. [30]Wang L VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML OncoImmunology 2018 7 9 e1469594 30228937 PMC6140587
  27. [31]Mulati K VISTA expressed in tumour cells regulates T cell function Br J Cancer 2018 120 1 115 127 30382166 PMC6325144
  28. [33]Kuklinski LF VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival Cancer Immunol Immunother 2018 67 7 1113 1121 29737375 PMC11028124
  29. [34]Jindal V Immunotherapy: a glimmer of hope for metastatic prostate cancer Chin Clin Oncol 2018 7 61 29860848
  30. [36]Zaravinos A Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer J Exp Clin Cancer Res 2019 38 1 1 18 31429779 PMC6701076
  31. [37]Vaupel P Mayer A Hypoxia in cancer: significance and impact on clinical outcome Cancer Metastasis Rev 2007 26 2 225 239 17440684
  32. [38]Hasmim M Cutting edge: hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-β1 J Immunol 2013 191 12 5802 5806 24227785
  33. [39]Chen, H., et al. Different clinical significance of novel B7 family checkpoints, VISTA and HHLA2, in human lung adenocarcinoma and colorectal cancer. in LABORATORY INVESTIGATION. 2019. NATURE PUBLISHING GROUP 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA. 35187955
  34. [40]Liao H Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer Oncol Lett 2018 16 3 3465 3472 30127950 PMC6096210
  35. [41]Zong L VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer Cancer Immunol Immunother 2019 69 1 33 42 31781843 PMC6949319
  36. [43]Le Mercier I VISTA regulates the development of protective antitumor immunity Cancer Res 2014 74 7 1933 1944 24691994 PMC4116689
  37. [44]Ru B TISIDB: an integrated repository portal for tumor–immune system interactions Bioinformatics 2019 35 20 4200 4202 30903160
  38. [45]Böger C The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: a future perspective for a combined gastric cancer therapy? OncoImmunology 2017 6 4 e1293215 28507801 PMC5414883
  39. [46]Loeser H The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma Oncoimmunology 2019 8 5 e1581546 31069143 PMC6492979
  40. [47]Zhang M VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma BMC Cancer 2018 18 1 511 29720116 PMC5932869
  41. [48]Weinstein JN The cancer genome atlas pan-cancer analysis project Nat Genet 2013 45 10 1113 24071849 PMC3919969
  42. [49]Blum A Wang P Zenklusen JC SnapShot: TCGA-analyzed tumors Cell 2018 173 2 530 29625059
  43. [50]Roychowdhury S Chinnaiyan AM Translating cancer genomes and transcriptomes for precision oncology CA Cancer J Clin 2016 66 1 75 88 26528881 PMC4713245
  44. [51]Tang Z GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses Nucleic Acids Res 2017 45 W1 W98 W102 28407145 PMC5570223
  45. [52]Tang Z GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis Nucleic Acids Res 2019 47 W1 W556 W560 31114875 PMC6602440
  46. [53]Gou R Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins J Transl Med 2019 17 1 275 31474227 PMC6717992

Cited by

Sorted by citations

Authors
Huang, X., Zhang, X., Li, E., Zhang, G., Wang, X., Tang, T., Bai, X., & Liang, T.
Affiliations
First Affiliated Hospital Zhejiang University (CN)
Corresponding author
  • Huang, Xing
  • Bai, Xueli
  • Liang, Tingbo
ORCID
Venue
Journal of Hematology & Oncology
Publisher
Springer Science and Business Media LLC
Published
2020-06-29
Volume
13
Issue
1
Pages
83-83
ISSN
1756-8722 (ISSN-L)
DOI
10.1186/s13045-020-00917-y
PMC
PMC7325042
OpenAlex
W3037339341
Cited by
231
References
4
Citations by year
2026: 27 · 2025: 22 · 2024: 55 · 2023: 48 · 2022: 44 · 2021: 32 · 2020: 2
FWCI
3.41
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (31970696, 81502975)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
VISTA, immune checkpoint, cancer immunotherapy, tumor immune cells, anti-cancer immunity, immune homeostasis, in silico analysis
MeSH terms
Immune Checkpoint Inhibitors, Immune Checkpoint Proteins, Clinical Trials as Topic, Female, Humans, Immunotherapy, Male, Neoplasm Proteins, Neoplasms, Organ Specificity, Prognosis, Gene Expression Regulation, Neoplastic, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Immunomodulation, Molecular Targeted Therapy, B7 Antigens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review